Brandon-Luke L Seagle1, Megan Dayno2, Anna E Strohl2, Stephen Graves2, Wilberto Nieves-Neira2, Shohreh Shahabi2. 1. Department of Obstetrics and Gynecology, Prentice Women's Hospital, Northwestern University, Feinberg School of Medicine, Chicago, IL, United States. Electronic address: brandon.seagle@northwestern.edu. 2. Department of Obstetrics and Gynecology, Prentice Women's Hospital, Northwestern University, Feinberg School of Medicine, Chicago, IL, United States.
Abstract
OBJECTIVE: To determine overall survival (OS) and factors associated with OS after pelvic exenteration for uterine cancer. METHODS: Women with uterine cancer who underwent exenteration (n=1160) were identified from the 1998-2011 National Cancer Data Base. Kaplan-Meier and multivariate Cox proportional-hazards survival analyses were performed to test for associations of potential explanatory variables with OS. Analyzed confounders included age, comorbidity score, insurance status, income, distance from home to treatment center, stage, distant and nodal metastasis, tumor size, surgical margin status, exenteration type, and treatment with radiation and/or chemotherapy. RESULTS: Among women with follow-up data (n=652), median (IQR) OS was 63.1 (42.2-107.2) and 17.6 (14.7-23.9) months for women with node-negative versus node-positive disease, respectively. Histology (p=1.5×10-4), grade (p=7.9×10-14), race (p=0.0002), lymph node status (p=1.0×10-14), surgical node evaluation (p=2.8×10-8), surgery for distant metastasis (p=0.004), distant metastasis at diagnosis (p=1.3×10-10), positive surgical margins (p=1.6×10-9), radiotherapy (p=0.004), and insurance status (p=6.5×10-6) were significantly associated with differential, unadjusted Kaplan-Meier OS estimates. Exenteration type was not associated with OS (p=0.357). By multivariate regression, increased age, positive surgical margins, nodal metastasis or unknown nodal status, higher histologic grade, and black race were associated with increased hazards for death. CONCLUSION: Exenteration may be curative for well-selected women with uterine cancer, particularly among women with pathologically negative lymph nodes.
OBJECTIVE: To determine overall survival (OS) and factors associated with OS after pelvic exenteration for uterine cancer. METHODS:Women with uterine cancer who underwent exenteration (n=1160) were identified from the 1998-2011 National Cancer Data Base. Kaplan-Meier and multivariate Cox proportional-hazards survival analyses were performed to test for associations of potential explanatory variables with OS. Analyzed confounders included age, comorbidity score, insurance status, income, distance from home to treatment center, stage, distant and nodal metastasis, tumor size, surgical margin status, exenteration type, and treatment with radiation and/or chemotherapy. RESULTS: Among women with follow-up data (n=652), median (IQR) OS was 63.1 (42.2-107.2) and 17.6 (14.7-23.9) months for women with node-negative versus node-positive disease, respectively. Histology (p=1.5×10-4), grade (p=7.9×10-14), race (p=0.0002), lymph node status (p=1.0×10-14), surgical node evaluation (p=2.8×10-8), surgery for distant metastasis (p=0.004), distant metastasis at diagnosis (p=1.3×10-10), positive surgical margins (p=1.6×10-9), radiotherapy (p=0.004), and insurance status (p=6.5×10-6) were significantly associated with differential, unadjusted Kaplan-Meier OS estimates. Exenteration type was not associated with OS (p=0.357). By multivariate regression, increased age, positive surgical margins, nodal metastasis or unknown nodal status, higher histologic grade, and black race were associated with increased hazards for death. CONCLUSION: Exenteration may be curative for well-selected women with uterine cancer, particularly among women with pathologically negative lymph nodes.
Authors: Alli M Straubhar; Andrew J Chi; Qin C Zhou; Alexia Iasonos; Olga T Filippova; Mario M Leitao; Ibraheem O Awowole; Nadeem R Abu-Rustum; Vance A Broach; Elizabeth L Jewell; Jaspreet S Sandhu; Yukio Sonoda Journal: Gynecol Oncol Date: 2021-09-10 Impact factor: 5.482
Authors: Veronika Seebacher; Andrea Rockall; Marielle Nobbenhuis; S Aslam Sohaib; Thomas Knogler; Rosa M Alvarez; Desiree Kolomainen; John H Shepherd; Clare Shaw; Desmond P Barton Journal: Arch Gynecol Obstet Date: 2021-11-03 Impact factor: 2.344
Authors: Ryan K Orosco; Viridiana J Tapia; Joseph A Califano; Bryan Clary; Ezra E W Cohen; Christopher Kane; Scott M Lippman; Karen Messer; Alfredo Molinolo; James D Murphy; John Pang; Assuntina Sacco; Kathryn R Tringale; Anne Wallace; Quyen T Nguyen Journal: Sci Rep Date: 2018-04-09 Impact factor: 4.379
Authors: L J Lauwerends; H Abbasi; T C Bakker Schut; P B A A Van Driel; J A U Hardillo; I P Santos; E M Barroso; S Koljenović; A L Vahrmeijer; R J Baatenburg de Jong; G J Puppels; S Keereweer Journal: Eur J Nucl Med Mol Imaging Date: 2022-02-01 Impact factor: 10.057